Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.


AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand

Global banking and finance news 28

AMRI today announced its ongoing commitment to do its part in support of public health needs amidst the COVID-19 pandemic. The company continues to focus on the safety of its employees, assuring supply of critical raw materials, active pharmaceutical ingredients (API), and drug product, while seeking additional ways to assist in the significant prevention and treatment efforts needed to counter the spread of COVID-19.

As such, in the immediate and near term, AMRI is increasing production of hydroxychloroquine sulfate API at its Rensselaer, N.Y., manufacturing facility to meet the rise in demand resulting from potential effectiveness of the product in treating COVID-19 symptoms.

AMRIs active Type II DMF for hydroxychloroquine sulfate (HCQ) is available to support increased need. The FDA authorized emergency use of HCQ to treat some hospitalized patients with COVID-19[1]. We look forward to working with our drug product producers, government agencies and associated health authorities globally to ensure access to this API, as needed.

AMRI is committed to supporting global public health needs and will continue to do our part during this critical time as an essential business in the health care industry.

About AMRI AMRI, a contract research development and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. AMRIs team combines scientific expertise and market-leading technology to provide a complete suite of solutions in discovery, development, analytical services, and API and drug product manufacturing.


Jane Byram

SCORR Marketing

(512) 626-2758


Recent Post

Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.